Cargando…

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy

PURPOSE: The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted to evaluate the efficacy and safety of anlot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tian, Lin, Feng, Huang, Yujing, Qian, Guowei, Yu, Wenxi, Hu, Haiyan, Ji, Tong, Tang, Lina, Yao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547547/ https://www.ncbi.nlm.nih.gov/pubmed/36217441 http://dx.doi.org/10.2147/CMAR.S378264

Ejemplares similares

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
por: Andres, R, et al.
Publicado: (2002)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
por: Lee, Min Jeong, et al.
Publicado: (2012)

Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
por: He, Wei, et al.
Publicado: (2016)

Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
por: Ji, Xiang, et al.
Publicado: (2022)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute
por: YU, WEN-XI, et al.
Publicado: (2014)

Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
por: Markers, Disease
Publicado: (2023)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
por: TAS, FARUK, et al.
Publicado: (2013)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
por: Jeon, Ye Won, et al.
Publicado: (2017)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort
por: Wu, Hongyang, et al.
Publicado: (2022)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy
por: Huang, Yujing, et al.
Publicado: (2016)

Satisfactory short‐term outcome after anlotinib and docetaxel chemotherapy in tongue cancer with N3 cervical lymph node metastasis: A case report
por: Deng, Yi, et al.
Publicado: (2019)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
por: Zhang, Ge, et al.
Publicado: (2021)

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
por: Park, Inkeun, et al.
Publicado: (2016)

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
por: Lee, Choong-kun, et al.
Publicado: (2015)

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
por: Seddon, Beatrice, et al.
Publicado: (2015)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
por: Starling, N, et al.
Publicado: (2007)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qk8ajopt9h32p7k2b8crf1qjvl